mitoglitazone   Click here for help

GtoPdb Ligand ID: 11303

Synonyms: MSDC-0160 | MSDC0160
Compound class: Synthetic organic
Comment: Mitoglitazone is a thiazolidinedione class compound. that was developed for the treatment of non-insulin-dependent diabetes mellitus [4]. It acts as an insulin sensitizer and modulates mitochondrial pyruvate transport by the mitochondrial pyruvate carrier [2-3]. Structurally it is an analogue of the approved antidiabetes drug pioglitazone.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 110.66
Molecular weight 370.1
XLogP 1.83
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCc1ccc(nc1)C(=O)COc1ccc(cc1)CC1SC(=O)NC1=O
Isomeric SMILES CCc1ccc(nc1)C(=O)COc1ccc(cc1)CC1SC(=O)NC1=O
InChI InChI=1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24)
InChI Key IRNJSRAGRIZIHD-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
ClinicalTrials.gov has records for completed Phase 2 studies of mitoglitazone.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00760578 A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator Phase 2 Interventional Metabolic Solutions Development Company
NCT01103414 Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients Phase 2 Interventional Metabolic Solutions Development Company 1
NCT01374438 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease Phase 2 Interventional Metabolic Solutions Development Company 3